ATE392903T1 - Impfstoff gegen pferdeherpesvirus - Google Patents

Impfstoff gegen pferdeherpesvirus

Info

Publication number: ATE392903T1
Authority: AT; Austria
Prior art keywords: herpes virus; vaccine against; equine herpes; against equine; vaccine
Prior art date: 2001-03-20

Application number

AT02713437T

Other languages

English (en)

Inventor

Mark Mellencamp

Original Assignee

Boehringer Ingelheim Vetmed

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-20

Filing date

2002-01-23

Publication date

2008-05-15

2002-01-23 Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed

2008-05-15 Application granted granted Critical

2008-05-15 Publication of ATE392903T1 publication Critical patent/ATE392903T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/27—Equine rhinopneumonitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16163—Methods of inactivation or attenuation by chemical treatment

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Tropical Medicine & Parasitology (AREA)
Biochemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT02713437T 2001-03-20 2002-01-23 Impfstoff gegen pferdeherpesvirus ATE392903T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/812,720 US6803041B2 (en)	2001-03-20	2001-03-20	Equine herpesvirus vaccine

Publications (1)

Publication Number	Publication Date
ATE392903T1 true ATE392903T1 (de)	2008-05-15

Family

ID=25210428

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02713437T ATE392903T1 (de)	2001-03-20	2002-01-23	Impfstoff gegen pferdeherpesvirus

Country Status (15)

Country	Link
US (3)	US6803041B2 (de)
EP (2)	EP1372712B1 (de)
JP (2)	JP4177112B2 (de)
KR (1)	KR100840525B1 (de)
AR (2)	AR032984A1 (de)
AT (1)	ATE392903T1 (de)
CA (1)	CA2441292C (de)
CY (1)	CY1108200T1 (de)
DE (1)	DE60226218T2 (de)
DK (2)	DK1372712T3 (de)
ES (2)	ES2305220T3 (de)
MX (1)	MXPA03008287A (de)
NZ (1)	NZ529012A (de)
PT (1)	PT1372712E (de)
WO (1)	WO2002074335A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6803041B2 (en) *	2001-03-20	2004-10-12	Boehringer Ingelheim Vetmedica, Inc.	Equine herpesvirus vaccine
JP2005075752A (ja) *	2003-08-29	2005-03-24	Nippon Inst For Biological Science	豚繁殖・呼吸障害症候群用ワクチン製剤
US7572620B2 (en)	2005-01-11	2009-08-11	Wisconsin Alumni Research Foundation	H3 equine influenza A virus
CA2626875A1 (en) *	2005-11-01	2007-05-10	Intervet International B.V.	Prime boost vaccine for the protection of equines against equine influenza
CA2732035A1 (en)	2008-07-30	2010-02-04	University Of Kentucky Research Foundation	Equine disease model for herpesvirus neurologic disease and uses thereof
EP2376628B1 (de)	2008-12-16	2018-05-16	Ology Bioservices, Inc.	Erzeugung von impfstoffe gegen influenza virus
WO2010144797A2 (en)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Influenza vaccines with enhanced immunogenicity and uses thereof
WO2011141443A1 (en) *	2010-05-11	2011-11-17	Intervet International B.V.	Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
PT3542819T (pt) *	2013-05-14	2021-10-14	Zoetis Services Llc	Composições de vacina inovadoras que compreendem oligonucleótidos imunoestimulantes
JP6560056B2 (ja) *	2015-08-07	2019-08-14	ウィスコンシンアルムニリサーチファンデイション	Ｈ３型ウマａ型インフルエンザウイルス
CA3080656A1 (en)	2017-10-30	2019-05-09	Baxalta GmbH	Environmentally compatible detergents for inactivation of lipid-enveloped viruses
AU2022321826A1 (en) *	2021-08-06	2024-01-25	Intervet International B.V.	Vaccine for equine herpesvirus

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3920811A (en) *	1972-12-22	1975-11-18	Cutter Lab	Adjuvant compositions
US4110433A (en)	1976-04-23	1978-08-29	Philips Roxane, Inc.	Equine rhinopneumonitis virus
US4083958A (en)	1976-09-13	1978-04-11	The University Of Kentucky Research Foundation	Inactivated equine rhinopneumonitis virus vaccine and use thereof
US4225582A (en)	1979-03-08	1980-09-30	The University Of Illinois Foundation	Vaccine for equine rhinopneumonitis
US4500513A (en) *	1979-05-15	1985-02-19	Miles Laboratories, Inc.	Influenza vaccine production in liquid cell culture
US4509949A (en)	1983-06-13	1985-04-09	The B. F. Goodrich Company	Water thickening agents consisting of copolymers of crosslinked acrylic acids and esters
EP0163696B1 (de)	1983-11-14	1992-11-25	Columbia Laboratories, Inc.	Verwendung eines bioadhesives
US5084271B1 (en)	1984-09-11	1997-08-05	Univ Melbourne	Vaccine for equine herpesvirus
US4758641A (en)	1987-02-24	1988-07-19	The B F Goodrich Company	Polycarboxylic acids with small amount of residual monomer
NZ224422A (en)	1987-05-05	1990-11-27	Molecular Eng Ass	Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5221722A (en)	1988-11-28	1993-06-22	The B. F. Goodrich Company	Crosslinked polyacrylic acid
US5292653A (en) *	1989-09-27	1994-03-08	Novagene, Inc.	Equine herpesvirus 1 tk mutants
GB9014950D0 (en)	1990-07-06	1990-08-29	Univ Glasgow	Ehv-4 glycoprotein vaccine
US6025181A (en)	1990-07-06	2000-02-15	University Court Of The University Of Glasgow	Equine herpesvirus-4TK mutant
AU8545391A (en)	1990-08-01	1992-03-02	Research Corporation Technologies, Inc.	The gene encoding equine herpesvirus type 1 glycoprotein d, its gene product, antibodies and their uses
US5462734A (en) *	1990-11-02	1995-10-31	Wisconsin Alumni Research Foundation	Bovine herpesvirus vaccine and method of using same
EP0532833A1 (de)	1991-05-28	1993-03-24	Miles Inc.	Pferde-Rhinopneumonitis Impfstoff
US6193983B1 (en)	1992-06-01	2001-02-27	The University Of Melbourne	Equine herpesvirus glycoproteins
ATE259417T1 (de)	1992-06-01	2004-02-15	Univ Melbourne	Immunologisches verfahren für die detektion von pferde-herpesvirus typ 1 und 4 glycoprotein g antikörper
US6225111B1 (en)	1992-08-07	2001-05-01	Schering Plough Veterinary Corp.	Recombinant equine herpesviruses
AUPN720195A0 (en)	1995-12-18	1996-01-18	University Of Melbourne, The	Equine rhinovirus 1 proteins
FR2751226B1 (fr)	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique contre les pathologies du cheval
US5853715A (en) *	1996-08-16	1998-12-29	Bayer Corporation	Cross-protective equine herpesvirus preparations and method of making and using the same
DE59811284D1 (de) *	1997-03-12	2004-06-03	Merck Patent Gmbh	Endstück für eine chromatographische säule
US5891705A (en) *	1997-04-08	1999-04-06	Pentose Pharmaceuticals, Inc.	Method for inactivating a virus
EP0978286A1 (de)	1998-08-07	2000-02-09	Bayer Corporation	Sich gegenseitig schützende Herpesviruszusammensetzungen vom Pferd und Verfahren zur deren Herstellung und Verwendung
US6803041B2 (en) *	2001-03-20	2004-10-12	Boehringer Ingelheim Vetmedica, Inc.	Equine herpesvirus vaccine

2001
- 2001-03-20 US US09/812,720 patent/US6803041B2/en not_active Expired - Lifetime
2002
- 2002-01-23 EP EP02713437A patent/EP1372712B1/de not_active Expired - Lifetime
- 2002-01-23 DE DE60226218T patent/DE60226218T2/de not_active Expired - Lifetime
- 2002-01-23 ES ES02713437T patent/ES2305220T3/es not_active Expired - Lifetime
- 2002-01-23 MX MXPA03008287A patent/MXPA03008287A/es active IP Right Grant
- 2002-01-23 NZ NZ529012A patent/NZ529012A/en not_active IP Right Cessation
- 2002-01-23 PT PT02713437T patent/PT1372712E/pt unknown
- 2002-01-23 ES ES08150506T patent/ES2428664T3/es not_active Expired - Lifetime
- 2002-01-23 EP EP08150506.7A patent/EP1923071B1/de not_active Expired - Lifetime
- 2002-01-23 KR KR1020037012273A patent/KR100840525B1/ko not_active Expired - Lifetime
- 2002-01-23 JP JP2002573042A patent/JP4177112B2/ja not_active Expired - Lifetime
- 2002-01-23 CA CA2441292A patent/CA2441292C/en not_active Expired - Lifetime
- 2002-01-23 DK DK02713437T patent/DK1372712T3/da active
- 2002-01-23 WO PCT/US2002/001644 patent/WO2002074335A2/en active IP Right Grant
- 2002-01-23 AT AT02713437T patent/ATE392903T1/de active
- 2002-01-23 DK DK08150506.7T patent/DK1923071T3/da active
- 2002-03-13 AR ARP020100906A patent/AR032984A1/es active Pending
2004
- 2004-07-23 US US10/897,984 patent/US7226604B2/en not_active Expired - Lifetime
2007
- 2007-04-26 US US11/789,919 patent/US20070196390A1/en not_active Abandoned
- 2007-05-14 JP JP2007127589A patent/JP4668951B2/ja not_active Expired - Lifetime
2008
- 2008-07-17 CY CY20081100745T patent/CY1108200T1/el unknown
2013
- 2013-05-31 AR ARP130101929 patent/AR091235A2/es unknown

Also Published As

Publication number	Publication date
PT1372712E (pt)	2008-05-29
US7226604B2 (en)	2007-06-05
MXPA03008287A (es)	2004-10-28
DK1372712T3 (da)	2008-08-04
WO2002074335A2 (en)	2002-09-26
AR032984A1 (es)	2003-12-03
US20070196390A1 (en)	2007-08-23
US20030206924A1 (en)	2003-11-06
CY1108200T1 (el)	2014-02-12
EP1923071A1 (de)	2008-05-21
WO2002074335A3 (en)	2003-07-17
EP1923071B1 (de)	2013-06-19
EP1372712B1 (de)	2008-04-23
CA2441292A1 (en)	2002-09-26
EP1372712A2 (de)	2004-01-02
DE60226218T2 (de)	2009-05-28
JP2007197470A (ja)	2007-08-09
JP4177112B2 (ja)	2008-11-05
AR091235A2 (es)	2015-01-21
DK1923071T3 (da)	2013-08-26
ES2305220T3 (es)	2008-11-01
JP4668951B2 (ja)	2011-04-13
KR100840525B1 (ko)	2008-06-24
KR20030085028A (ko)	2003-11-01
CA2441292C (en)	2012-03-20
ES2428664T3 (es)	2013-11-08
NZ529012A (en)	2005-08-26
US20050084502A1 (en)	2005-04-21
DE60226218D1 (de)	2008-06-05
JP2004525923A (ja)	2004-08-26
US6803041B2 (en)	2004-10-12

Publication	Publication Date	Title
DE60024893D1 (de)	2006-01-19	Impfstoff gegen HPV
CY2016018I1 (el)	2016-12-14	Εμβολιο κατα του ιου του δυτικου νειλου
ATE287728T1 (de)	2005-02-15	Adjuvierte rekombinante lebendimpfstoffe gegen influenza- oder herpesviren
EP1603590A4 (de)	2008-08-27	Influenza-virus-vakzine
DK1390066T3 (da)	2012-07-16	Vaccinesammensætning
NO20021431D0 (no)	2002-03-21	Intranasal influensavirusvaksine
DK1427444T3 (da)	2013-11-04	West-nil-vaccine
ATE420159T1 (de)	2009-01-15	Grippe-impfstoffzusammensetzung
NO20044326D0 (no)	2004-10-12	Virale antigener
EP1458242A4 (de)	2006-06-07	Polyvalente konjugatvakzine gegen krebs
EP1307130A4 (de)	2005-01-12	Impfstoff gegen menschlichen immunschwächevirus
NO20033882D0 (no)	2003-09-02	Vaksine
EP1423141A4 (de)	2005-08-03	Vakzine
DK1523329T3 (da)	2013-10-14	Viruspartikeladjuvant
NO20030239D0 (no)	2003-01-17	Modifisert virus
IL158428A0 (en)	2004-05-12	Vaccine composition comprising at least one hiv virus antigen
IS7831A (is)	2005-04-28	Bóluefni
ATE392903T1 (de)	2008-05-15	Impfstoff gegen pferdeherpesvirus
NO20033829L (no)	2003-10-27	Virusdrepende preparater
DE60328408D1 (de)	2009-08-27	Impfstoff
ATE437656T1 (de)	2009-08-15	Impfstoff gegen das maul- und klauensäure-virus
DE60334226D1 (de)	2010-10-28	Vakzine gegen infektiöse katzen-peritonitis
DE60125927D1 (de)	2007-02-22	Impfstoffe gegen hiv
NO20051561D0 (no)	2005-03-23	Vaksine
IS2797B (is)	2012-08-15	Bóluefni gegn ISA-veiru

Legal Events

Date	Code	Title	Description
2008-11-15	UEP	Publication of translation of european patent specification	Ref document number: 1372712 Country of ref document: EP

Date

Code

Title

Description

2008-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1372712

Country of ref document: EP